Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy

Yasoo Sugiura,1 Etsuo Nemoto,1 Osamu Kawai,2 Yasuyuki Ohkubo,2 Hisae Fusegawa,2 Shizuka Kaseda1 1Department of Pulmonary and Thoracic Surgery, 2Department of Respiratory Medicine, Kanagawa National Hospital, Hadano, Japan Background: Gefitinib is known as one of the agents for treating patients with...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sugiura Y, Nemoto E, Kawai O, Ohkubo Y, Fusegawa H, Kaseda S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/78374b2549a942babf80989947c6b5ba
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:78374b2549a942babf80989947c6b5ba
record_format	dspace
spelling	oai:doaj.org-article:78374b2549a942babf80989947c6b5ba2021-12-02T05:34:29ZGefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy1179-2728https://doaj.org/article/78374b2549a942babf80989947c6b5ba2013-06-01T00:00:00Zhttp://www.dovepress.com/gefitinib-frequently-induces-liver-damage-in-patients-with-lung-adenoc-a13302https://doaj.org/toc/1179-2728Yasoo Sugiura,1 Etsuo Nemoto,1 Osamu Kawai,2 Yasuyuki Ohkubo,2 Hisae Fusegawa,2 Shizuka Kaseda1 1Department of Pulmonary and Thoracic Surgery, 2Department of Respiratory Medicine, Kanagawa National Hospital, Hadano, Japan Background: Gefitinib is known as one of the agents for treating patients with both advanced lung cancer and an epidermal growth-factor receptor mutation. In the epidermal growth-factor receptor-mutant advanced non-small-cell lung cancer population, gefitinib therapy has been associated with increased response rate, longer progression-free survival, and better quality of life compared to other anticancer drugs. However, gefitinib has to be discontinued for patients in whom adverse events occur, even if it is still effective. Here, we retrospectively assessed the clinical course of patients receiving gefitinib therapy, with a particular focus on liver damage. Patients and methods: Of 24 Asian patients treated with 250 mg gefitinib daily at Kanagawa National Hospital, Japan, between January 2008 and June 2012, grade 3 liver damage (Common Terminology Criteria for Adverse Events, version 4.0) occurred in nine and were eligible for our assessment. The regimen was subsequently changed to alternate-day administration. The relationships between liver damage and each clinical factor were retrospectively examined using Fisher’s exact test. Results: Of the nine patients with liver damage, seven had previous exposure to another anticancer drug. There was a significant relationship between the incidence of liver damage and previous chemotherapy (P = 0.009). The objective response rates of patients treated with daily gefitinib 250 mg and alternate-day gefitinib following liver damage were 66.7% and 46.7%, respectively; these were not significantly different (P = 0.597). Conclusion: Gefitinib for advanced adenocarcinoma patients who have previously undergone chemotherapy should be used cautiously and liver function monitored closely, because it frequently induces significant liver damage. The alternate-day administration of gefitinib may be a suitable option for patients in whom daily gefitinib therapy induces liver damage. Keywords: gefitinib, liver damage, adjuvant chemotherapy, previous chemotherapy, alternate-day administrationSugiura YNemoto EKawai OOhkubo YFusegawa HKaseda SDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol 2013, Iss default, Pp 9-14 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Sugiura Y Nemoto E Kawai O Ohkubo Y Fusegawa H Kaseda S Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy
description	Yasoo Sugiura,1 Etsuo Nemoto,1 Osamu Kawai,2 Yasuyuki Ohkubo,2 Hisae Fusegawa,2 Shizuka Kaseda1 1Department of Pulmonary and Thoracic Surgery, 2Department of Respiratory Medicine, Kanagawa National Hospital, Hadano, Japan Background: Gefitinib is known as one of the agents for treating patients with both advanced lung cancer and an epidermal growth-factor receptor mutation. In the epidermal growth-factor receptor-mutant advanced non-small-cell lung cancer population, gefitinib therapy has been associated with increased response rate, longer progression-free survival, and better quality of life compared to other anticancer drugs. However, gefitinib has to be discontinued for patients in whom adverse events occur, even if it is still effective. Here, we retrospectively assessed the clinical course of patients receiving gefitinib therapy, with a particular focus on liver damage. Patients and methods: Of 24 Asian patients treated with 250 mg gefitinib daily at Kanagawa National Hospital, Japan, between January 2008 and June 2012, grade 3 liver damage (Common Terminology Criteria for Adverse Events, version 4.0) occurred in nine and were eligible for our assessment. The regimen was subsequently changed to alternate-day administration. The relationships between liver damage and each clinical factor were retrospectively examined using Fisher’s exact test. Results: Of the nine patients with liver damage, seven had previous exposure to another anticancer drug. There was a significant relationship between the incidence of liver damage and previous chemotherapy (P = 0.009). The objective response rates of patients treated with daily gefitinib 250 mg and alternate-day gefitinib following liver damage were 66.7% and 46.7%, respectively; these were not significantly different (P = 0.597). Conclusion: Gefitinib for advanced adenocarcinoma patients who have previously undergone chemotherapy should be used cautiously and liver function monitored closely, because it frequently induces significant liver damage. The alternate-day administration of gefitinib may be a suitable option for patients in whom daily gefitinib therapy induces liver damage. Keywords: gefitinib, liver damage, adjuvant chemotherapy, previous chemotherapy, alternate-day administration
format	article
author	Sugiura Y Nemoto E Kawai O Ohkubo Y Fusegawa H Kaseda S
author_facet	Sugiura Y Nemoto E Kawai O Ohkubo Y Fusegawa H Kaseda S
author_sort	Sugiura Y
title	Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy
title_short	Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy
title_full	Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy
title_fullStr	Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy
title_full_unstemmed	Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy
title_sort	gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/78374b2549a942babf80989947c6b5ba
work_keys_str_mv	AT sugiuray gefitinibfrequentlyinducesliverdamageinpatientswithlungadenocarcinomapreviouslytreatedbychemotherapy AT nemotoe gefitinibfrequentlyinducesliverdamageinpatientswithlungadenocarcinomapreviouslytreatedbychemotherapy AT kawaio gefitinibfrequentlyinducesliverdamageinpatientswithlungadenocarcinomapreviouslytreatedbychemotherapy AT ohkuboy gefitinibfrequentlyinducesliverdamageinpatientswithlungadenocarcinomapreviouslytreatedbychemotherapy AT fusegawah gefitinibfrequentlyinducesliverdamageinpatientswithlungadenocarcinomapreviouslytreatedbychemotherapy AT kasedas gefitinibfrequentlyinducesliverdamageinpatientswithlungadenocarcinomapreviouslytreatedbychemotherapy
_version_	1718400358042042368

Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy

Ejemplares similares